Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company warned Maryland labor regulators this week.
The Rockville-based biopharmaceuticals company, which employed as many as 1,000 people up until the acquisition, is in the process of integrating with GSK, a spokesman said.
Previously, the company disclosed in September it would cut 114 positions by the end of this month. A third round of cuts are planned for early next year, but the company did not disclose a precise figure to the Maryland Department of Labor, Licensing and Regulation, which tracks mass layoffs among employers in the state.
Gus.sentementes@baltsun.com
Twitter.com/gussent
Text BUSINESS to 70701 to get Baltimore Sun Business text alerts
The Rockville-based biopharmaceuticals company, which employed as many as 1,000 people up until the acquisition, is in the process of integrating with GSK, a spokesman said.
-
How much do Baltimore-area workers earn? [Pictures]
-
Jobs with six-figure salaries [Pictures]
- People on the Move archive
-
-
Health Professionals on the Move
-
Pictures: Jobs in health care
-
Most sleep-deprived jobs
-
See more photos »
- Unemployment
- Labor Legislation
- Job Layoffs
-
See more topics »
-
-
14200 Shady Grove Road, Rockville, MD 20850
Previously, the company disclosed in September it would cut 114 positions by the end of this month. A third round of cuts are planned for early next year, but the company did not disclose a precise figure to the Maryland Department of Labor, Licensing and Regulation, which tracks mass layoffs among employers in the state.
Gus.sentementes@baltsun.com
Twitter.com/gussent
Text BUSINESS to 70701 to get Baltimore Sun Business text alerts
